Serum Values of Pepsinogens and Antibodies to Helicobacter Pylori in Relation to a History of Peptic Ulcer Disease and NSAID Use

References

• Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastro-enterology 1971; 61: 185–8
   PubMed Web of Science ®Google Scholar
• Samloff I M, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973; 65: 36–42
   PubMed Web of Science ®Google Scholar
• Samloff I M, Vans K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. Gastroenterology 1982; 83: 204–9
   PubMed Web of Science ®Google Scholar
• Peña A S, Endtz HPh, Offerhaus G JA, Hoogenboom-Verdegaal A, Van Duyn W, de Vargas M, et al. Value of serology (Elisa and Immunoblotting) for the diagnosis of Campylobacter pylori infection. Digestion 1989; 44: 131–41
   PubMed Web of Science ®Google Scholar
• Perez-Perez G I, Dwarkin B, Chodos J, Blaser MJ. Campylobacter pylon-specific serum antibodies in humans. Ann Intern Med 1988; 109: 11–7
   PubMed Web of Science ®Google Scholar
• Taha A S, Reid J, Boothmann P, Gemmell C G, Fee F D, Sturrock R D, et al. Serological diagnosis of Helicobacter pylori-evaluation of four tests in the presence or absence of non-steroidal anti-inflammatory drugs. Gut 1993; 34: 461–5
   PubMed Web of Science ®Google Scholar
• Biemond I, Jansen J BMJ, Crobach L FSJ, Kreuning J, Lamers C BHW. Radioimmunoassay of human pepsinogen A and pepsinogen C. J Clin Chem Clin Biochem 1989; 27: 19–25
   PubMedGoogle Scholar
• Ichinose M, Miki K, Furihata C, Kageyama T, Niwa H, Oka H, et al. Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin Chin Acta 1982; 126: 183–91
   PubMed Web of Science ®Google Scholar
• Samloff I M, Liebman W M, Panitch HM. Serum group I pepsinogens by radioimmunoassay in control subjects and patients with peptic ulcer. Gastroenterology 1975; 69: 83–90
   PubMed Web of Science ®Google Scholar
• Veenendaal R A, Biemond I, Pena A S, Van Duyn W, Kreuning J, Lamers C BHW. The influence of age and Helicobacter pylori infection on serum pepsinogens in healthy blood transfusion donors. Gut 1992; 33: 452–5
   PubMed Web of Science ®Google Scholar
• Armstrong C P, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527–32
   PubMed Web of Science ®Google Scholar
• Skander M P, Ryan FP. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. Br Med J 1988; 297: 833–4
   PubMed Web of Science ®Google Scholar
• Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322: 909–16
   PubMed Web of Science ®Google Scholar
• Fries J F, Williams C A, Bloch D A, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med 1991; 91: 213–22
   PubMed Web of Science ®Google Scholar
• Llewellyn J G, Pritchard MH. Influence of age and disease state in non-steroidal anti-inflammatory drug associated gastric bleeding. J Rheumatol 1988; 15: 691–3
   PubMedGoogle Scholar
• Roth S H, Benett RE. Non-steroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987; 147: 2093–100
   PubMedGoogle Scholar
• Collier DStJ, Pain JA. Non-steroidal anti-inflammatory drugs and peptic ulcer performation. Gut 1985; 26: 359–63
   PubMed Web of Science ®Google Scholar
• Janssen M, Dijkmans B AC, van der Sluys F A, et al. Upper gastro-intestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol 1992; 31: 747–52
   PubMedGoogle Scholar
• Sipponen P, Varis K, Fraki O, Korri U-M, Seppälä K, Siurala M. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol 1990; 25: 966–73
   PubMed Web of Science ®Google Scholar
• Sipponen P. Chronic gastritis and ulcer risk. Scand J Gastroenterol 1990; 25: 193–6
   PubMed Web of Science ®Google Scholar
• Borch K, Axelsson C K, Halgreen H, Damkjaer Nielsen M, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: A sensitive test for atrophic gastritis. Scand J Gastroenterol 1989; 24: 870–6
   PubMed Web of Science ®Google Scholar
• Kosunen T U, Seppälä K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893–5
   PubMed Web of Science ®Google Scholar
• Dooley C P, Cohen H. The clinical significance of campylob-acter pylori. Ann Intern Med 1988; 108: 70–9
   PubMed Web of Science ®Google Scholar
• Blaser MJ. Helicobacter pylori and the pathogenesis of gastro-duodenal inflammation. J Infect Dis 1990; 161: 626–33
   PubMed Web of Science ®Google Scholar
• Taha A S, Natshabendi I, Lee F D, Sturrock R D, Russell RI. Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs -comparison and correlation with peptic ulceration. J Clin Pathol 1992; 45: 135–9
   PubMedGoogle Scholar
• Sobala G M, King R FG, Axon A TR, Dixon MF. Reflux gastritis in the intact stomach. J Clin Pathol 1990; 43: 303–6
   PubMed Web of Science ®Google Scholar
• Hengels K J, Zeidler H, Samloff IM. Asymptomatic gastric side effects of Nonsteroidal anti-inflammatory drugs: Detection by radioimmunoassay of serum pepsinogens. Gastroenterology 1985; 94: 1417, Abstract
   Google Scholar
• Kullich W, Pöllmann G, Ch Zmerekar, Klein G. Stellenwert der Bestimmung von Pepsinogen I im Serum als Screenings-methode für Früherkennung gastroduodenalers Läsionen und als Verlaufskontrolle under der Therapie mit nicht-steroidale Antirheumatika. Z Rheumatol 1991; 50: 39–45
   Google Scholar
• Shorrock C J, Rees W DW. Mucosal adaptation to indometh-acin induced gastric damage in man-studies on morphology, blood flow and prostaglandin E2 metabolism. Gut 1992; 33: 164–9
   PubMed Web of Science ®Google Scholar